|Bid||42.76 x 2200|
|Ask||42.78 x 800|
|Day's Range||42.72 - 43.12|
|52 Week Range||35.30 - 45.69|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||49.96|
|Forward Dividend & Yield||1.40 (3.26%)|
|1y Target Est||46.14|
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis.
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Patients in a reference group on chemotherapy only lived a median 10.3 months in the so-called Caspian trial, it said. "There is a wide recognition that in small cell lung cancer there is very much a need for new therapies," said Dave Fredrickson, head of the company's oncology business.
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.
Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch
Sep.09 -- AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's expedited approval of new therapies to meet unmet medical demands. Leon Wang, it's executive vice president overseeing international markets, spoke exclusively to Selina Wang on "Bloomberg Daybreak: Asia.